The antineoplastic and therapeutic effects of quinoline compounds against ehrlich ascites carcinoma in mice.

AIM: One of the preferred scaffolds, 8-hydroxyquinoline, has been investigated synthetically by functioning at various places by several groups in pursuit of medicinally significant compounds. This research's objective is to investigate the antineoplastic and therapeutic effects of 8-hydroxy-7-carboxaldehydequinoline against (EAC) cells.

METHODS &

RESULTS

One hundred mice were detached equally into five groups [(G1) negative control; (G2) 1% DMSO; (G3) Drug group; (G4) EAC group; (G5) EAC+ tested compound]. Docking study was performed, and the antitumor effect of the compound was evaluated by hematological, biochemical, antioxidant, histopathological parameters, and levels of caspase-3 and TNF-α. The docking study showed effective interaction between tested compounds and receptors of catalase, breast cancer, and caspase3. In vivo, treatment significantly restored hematological parameters, reduced liver enzymes, lipid profiles, cardiac biomarkers, urea, creatinine, malonaldehyde, and nitric oxide, while increasing total protein, superoxide dismutase, reduced glutathione, catalase, and total antioxidant capacity levels. Our findings showed that treatment with tested compound demonstrated apoptotic effect via rising in caspase3 and declining in TNF-α levels. Histopathological examination backed with our findings.

CONCLUSION

With an effective safety profile, 8-hydroxy-7-carboxaldehydequinoline exhibits potential antineoplastic efficacy against EAC through apoptotic and antioxidant mechanisms.